Skip to main content

Advertisement

SpringerLink
Log in

Advanced MR Imaging in Neuro-oncology

  • Review Article
  • Published:
Clinical Neuroradiology Aims and scope Submit manuscript

Abstract

The value of magnetic resonance (MR) imaging for the clinical management of brain tumour patients has greatly increased in recent years through the introduction of functional MR sequences. Previously, MR imaging for brain tumours relied for the most part on contrast-enhanced T1-weighted MR sequences but today with the help of advanced functional MR sequences, the pathophysiological aspects of tumour growth can be directly visualised and investigated. This article will present the pathophysiological background of the MR sequences relevant to neuro-oncological imaging as well as potential clinical applications. Ultimately, we take a look at possible future developments for ultra-high-field MR imaging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF. Pros and cons of current brain tumor imaging. Neuro Oncol. 2014;16 Suppl 7:2–11.

    Article  Google Scholar 

  2. Niendorf HP, Laniado M, Semmler W, Schörner W, Felix R. Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors. AJNR Am J Neuroradiol. 1987;8(5):803–15.

    CAS  PubMed  Google Scholar 

  3. Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer G, Wick W, Bendszus M, Radbruch A. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology. 2014;82(19):1684–92.

    Article  CAS  PubMed  Google Scholar 

  4. Bähr O, Harter PN, Weise LM, You SJ, Mittelbronn M, Ronellenfitsch MW, Rieger J, Steinbach JP, Hattingen E. Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. Neurology. 2014;83(3):227–34.

    Article  PubMed  Google Scholar 

  5. Bähr O, Hattingen E, Rieger J, Steinbach JP. Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma. Neuro Oncol. 2011;13(9):1020–9.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72.

    Article  PubMed  Google Scholar 

  7. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277–80.

    CAS  PubMed  Google Scholar 

  8. Radbruch A, Lutz K, Wiestler B, Bäumer P, Heiland S, Wick W, Bendszus M. Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro Oncol. 2012;14(2):222–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Reichenbach JR, Haacke EM. High-resolution BOLD venographic imaging: a window into brain function. NMR Biomed. 2001;14(7–8):453–67.

    Article  CAS  PubMed  Google Scholar 

  10. Reichenbach JR, Venkatesan R, Schillinger DJ, Kido DK, Haacke EM. Small vessels in the human brain: MR venography with deoxyhemoglobin as an intrinsic contrast agent. Radiology. 1997;204(1):272–7.

    Article  CAS  PubMed  Google Scholar 

  11. Kim HS, Jahng GH, Ryu CW, Kim SY. Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions: preliminary study. AJNR Am J Neuroradiol. 2009;30(8):1574–9.

    Article  CAS  PubMed  Google Scholar 

  12. Park MJ, Kim HS, Jahng GH, Ryu CW, Park SM, Kim SY. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging. AJNR Am J Neuroradiol. 2009;30(7):1402–8.

    Article  CAS  PubMed  Google Scholar 

  13. Deistung A, Schweser F, Wiestler B, Abello M, Roethke M, Sahm F, Wick W, Nagel AM, Heiland S, Schlemmer HP, Bendszus M, Reichenbach JR, Radbruch A. Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma. PLoS One. 2013;8(3):e57924.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Kickingereder P, Wiestler B, Sahm F, Heiland S, Roethke M, Schlemmer HP, Wick W, Bendszus M, Radbruch A. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging. Radiology. 2014;272(3):843–50.

    Article  PubMed  Google Scholar 

  15. Radbruch A, Graf M, Kramp L, Wiestler B, Floca R, Bäumer P, Roethke M, Stieltjes B, Schlemmer HP, Heiland S, Bendszus M. Differentiation of brain metastases by percentagewise quantification of intratumoral-susceptibility-signals at 3 T. Eur J Radiol. 2012;81(12):4064–8.

    Article  PubMed  Google Scholar 

  16. Mohammed W, Xunning H, Haibin S, Jingzhi M. Clinical applications of susceptibility-weighted imaging in detecting and grading intracranial gliomas: a review. Cancer Imaging. 2013;13:186–95.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Lupo JM, Essock-Burns E, Molinaro AM, Cha S, Chang SM, Butowski N, Nelson SJ. Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. Neuro Oncol. 2013;15(4):480–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Schweser F, Deistung A, Lehr BW, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys. 2010;37(10):5165–78.

    Article  PubMed  Google Scholar 

  19. Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, Johnson G. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004;25(5):746–55.

    PubMed  Google Scholar 

  20. Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML, Miller DC, Golfinos JG, Zagzag D, Johnson G. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247(2):490–8.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Vidiri A, Pace A, Fabi A, Maschio M, Latagliata GM, Anelli V, Piludu F, Carapella CM, Giovinazzo G, Marzi S. Early perfusion changes in patients with recurrent high-grade brain tumor treated with bevacizumab: preliminary results by a quantitative evaluation. J Exp Clin Cancer Res. 2012;31:33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Kickingereder P, Wiestler B, Burth S, Wick A, Nowosielski M, Heiland S, Schlemmer HP, Wick W, Bendszus M, Radbruch A. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro Oncol. 2015;17:1139–47.

    Article  PubMed  Google Scholar 

  23. Tsien C, Galbán CJ, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC, Junck L, Meyer CR, Rehemtulla A, Lawrence T, Ross BD. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol. 2010;28(13):2293–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Radbruch A, Fladt J, Kickingereder P, Wiestler B, Nowosielski M, Bäumer P, Schlemmer HP, Wick A, Heiland S, Wick W, Bendszus M. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro Oncol. 2015;17(1):151–9.

    Article  PubMed  Google Scholar 

  25. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507.

    Article  CAS  PubMed  Google Scholar 

  26. Heiland S, Wick W, Bendszus M. Perfusion magnetic resonance imaging for parametric response maps in tumors: is it really that easy? J Clin Oncol. 2010. 28(29):e591. (author reply e592).

    Article  PubMed  Google Scholar 

  27. Radbruch A, Bendszus M, Wick W, Heiland S. Comment to: Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma: pitfalls in perfusion MRI in brain tumors: Tsien C, Galban CJ, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC, Junck L, Meyer CR, Rehemtulla A, Lawrence T, Ross BD. J Clin Oncol. 2010;28:2293–9. Clin Neuroradiol. 2010;20(3):183–4.

    Article  CAS  PubMed  Google Scholar 

  28. Blasel S, Jurcoane A, Franz K, Morawe G, Pellikan S, Hattingen E. Elevated peritumoural rCBV values as a mean to differentiate metastases from high-grade gliomas. Acta Neurochir (Wien). 2010;152(11):1893–9.

    Article  Google Scholar 

  29. Stecco A, Pisani C, Quarta R, Brambilla M, Masini L, Beldì D, Zizzari S, Fossaceca R, Krengli M, Carriero A. DTI and PWI analysis of peri-enhancing tumoral brain tissue in patients treated for glioblastoma. J Neurooncol. 2011;102(2):261–71.

    Article  PubMed  Google Scholar 

  30. Hakyemez B, Erdogan C, Gokalp G, Dusak A, Parlak M. Solitary metastases and high-grade gliomas: radiological differentiation by morphometric analysis and perfusion-weighted MRI. Clin Radiol. 2010;65(1):15–20.

    Article  CAS  PubMed  Google Scholar 

  31. Xu XX, Li B, Yang HF, Du Y, Li Y, Wang WX, Zheng HJ, Gong QY. Can diffusion-weighted imaging be used to differentiate brain abscess from other ring-enhancing brain lesions? A meta-analysis. Clin Radiol. 2014;69(9):909–15.

    Article  PubMed  Google Scholar 

  32. Gupta RK, Cloughesy TF, Sinha U, Garakian J, Lazareff J, Rubino G, Rubino L, Becker DP, Vinters HV, Alger JR. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol. 2000;50(3):215–26.

    Article  CAS  PubMed  Google Scholar 

  33. Sugahara T KY, Kochi M, Ikushima I, Shigematu Y, Hirai T, Okuda T, Liang L, Ge Y, Komohara Y, Ushio Y, Takahashi M. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999;9(1):53–60.

    Article  PubMed  Google Scholar 

  34. Gupta R, Sinha U, Cloughesy TF, Alger JR. Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magn Reson Med. 1999;41:2–7.

    Article  CAS  PubMed  Google Scholar 

  35. Lutz K, Wiestler B, Graf M, Bäumer P, Floca R, Schlemmer HP, Heiland S, Wick W, Bendszus M, Radbruch A. Infiltrative patterns of glioblastoma: Identification of tumor progress using apparent diffusion coefficient histograms. J Magn Reson Imaging. 2014;39(5):1096–103.

    Article  PubMed  Google Scholar 

  36. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252(1):182–9.

    Article  PubMed  Google Scholar 

  37. Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, Xue X, Goldin J, Brown MS, Nghiemphu PL, Tran A, Cloughesy TF. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011;32(5):882–9.

    Article  CAS  PubMed  Google Scholar 

  38. Provenzale JM, McGraw P, Mhatre P, Guo AC, Delong D. Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. Radiology. 2004;232(2):451–60.

    Article  PubMed  Google Scholar 

  39. Deng Z, Yan Y, Zhong D, Yang G, Tang W, Lü F, Xie B, Liu B. Quantitative analysis of glioma cell invasion by diffusion tensor imaging. J Clin Neurosci. 2010;17(12):1530–6.

    Article  PubMed  Google Scholar 

  40. Baek HJ, Kim HS, Kim N, Choi YJ, Kim YJ. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas. Radiology. 2012;264(3):834–43.

    Article  PubMed  Google Scholar 

  41. Radbruch A, Schlemmer HP. Application of ultrahigh-field MRI in neuro-oncology. Radiologe. 2013;53(5):411–4.

    Article  CAS  PubMed  Google Scholar 

  42. Balchandani P, Naidich TP. Ultra-high-field MR neuroimaging. AJNR Am J Neuroradiol. 2015;36:1204–15.

    Article  CAS  PubMed  Google Scholar 

  43. Radbruch A, Eidel O, Wiestler B, Paech D, Burth S, Kickingereder P, Nowosielski M, Bäumer P, Wick W, Schlemmer HP, Bendszus M, Ladd M, Nagel AM, Heiland S. Quantification of tumor vessels in glioblastoma patients using time-of-flight angiography at 7 T: a feasibility study. PLoS One. 2014;9:e110727.

  44. Nagel AM, Bock M, Hartmann C, Gerigk L, Neumann JO, Weber MA, Bendszus M, Radbruch A, Wick W, Schlemmer HP, Semmler W, Biller A. The potential of relaxation-weighted sodium magnetic resonance imaging as demonstrated on brain tumors. Invest Radiol. 2011;46(9):539–47.

    Article  PubMed  Google Scholar 

  45. Nagel AM, Lehmann-Horn F, Weber MA, Jurkat-Rott K, Wolf MB, Radbruch A, Umathum R, Semmler W. In vivo 35Cl MR imaging in humans: a feasibility study. Radiology. 2014;271(2):585–95.

    Article  PubMed  Google Scholar 

  46. Hoffmann SH, Radbruch A, Bock M, Semmler W, Nagel AM. Direct (17)O MRI with partial volume correction: first experiences in a glioblastoma patient. MAGMA. 2014;27(6):579–87.

    Article  CAS  PubMed  Google Scholar 

  47. Paech D, Zaiss M, Meissner JE, Windschuh J, Wiestler B, Bachert P, Neumann JO, Kickingereder P, Schlemmer HP, Wick W, Nagel AM, Heiland S, Ladd ME, Bendszus M, Radbruch A. Nuclear Overhauser enhancement mediated chemical exchange saturation transfer imaging at 7 T in glioblastoma patients. PLoS One. 2014;9(8):e104181.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Windschuh J, Zaiss M, Meissner JE, Paech D, Radbruch A, Ladd ME, Bachert P. Correction of B1-inhomogeneities for relaxation-compensated CEST imaging at 7 T. NMR Biomed. 2015;28(5):529–37.

    Article  PubMed  Google Scholar 

  49. Zaiss M, Windschuh J, Paech D, Meissner JE, Burth S, Schmitt B, Kickingereder P, Wiestler B, Wick W, Bendszus M, Schlemmer HP, Ladd ME, Bachert P, Radbruch A. Relaxation-compensated CEST-MRI of the human brain at 7 T: unbiased insight into NOE and amide signal changes in human glioblastoma. Neuroimage. 2015;112:180–8.

    Article  PubMed  Google Scholar 

  50. Zaiss M, Kunz P, Goerke S, Radbruch A, Bachert P. MR imaging of protein folding in vitro employing nuclear-Overhauser-mediated saturation transfer. NMR Biomed. 2013;26(12):1815–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuroradiology, University of Heidelberg, INF 400, 69120, Heidelberg, Germany

    A. Radbruch & M. Bendszus

Authors
  1. A. Radbruch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Bendszus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Radbruch.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Radbruch, A., Bendszus, M. Advanced MR Imaging in Neuro-oncology. Clin Neuroradiol 25 (Suppl 2), 143–149 (2015). https://doi.org/10.1007/s00062-015-0439-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00062-015-0439-2

Keywords

Search

Navigation